Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/214816
Title: Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Author: Prat Aparicio, Aleix
Chaudhury, Anwesha
Solovieff, Nadia
Paré Brunet, Laia
Martínez Pérez, Debora
Chic Ruche, Nuria
Martínez Sáez, Olga
Brasó Maristany, Fara
Lteif, Agnes
Taran, Tetiana
Babbar, Naveen
Su, Fei
Keywords: Càncer de mama
Receptors d'hormones
Breast cancer
Hormone receptors
Issue Date: 1-May-2021
Publisher: American Society of Clinical Oncology (ASCO) Publications
Abstract: PURPOSE: The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently unknown. We evaluated the association of intrinsic subtypes with progression-free survival (PFS) in the MONALEESA trials. METHODS: A retrospective and exploratory PAM50-based analysis of tumor samples from the phase III MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials was undertaken. The prognostic relationship of PAM50-based subtypes with PFS and risk of disease progression by subtype and treatment were evaluated using a multivariable Cox proportional hazards model, adjusting for age, prior chemotherapy, performance status, visceral disease, bone-only metastases, histological grade, number of metastatic sites, prior endocrine therapy, and de novo metastatic disease. RESULTS: Overall, 1,160 tumors from the RIB (n = 672) and placebo (n = 488) cohorts were robustly profiled. Subtype distribution was luminal A (LumA), 46.7%; luminal B (LumB), 24.0%; normal-like, 14.0%; HER2-enriched (HER2E), 12.7%; and basal-like, 2.6% and was generally consistent across treatment arms and trials. The associations between subtypes and PFS were statistically significant in both arms (P < .001). The risks of disease progression for LumB, HER2E, and basal-like subtypes were 1.44, 2.31, and 3.96 times higher compared with those for LumA, respectively. All subtypes except basal-like demonstrated significant PFS benefit with RIB. HER2E (hazard ratio [HR], 0.39; P < .0001), LumB (HR, 0.52; P < .0001), LumA (HR, 0.63; P = .0007), and normal-like (HR, 0.47; P = .0005) subtypes derived benefit from RIB. Patients with basal-like subtype (n = 30) did not derive benefit from RIB (HR, 1.15; P = .77). CONCLUSION: In this retrospective exploratory analysis of hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer, each intrinsic subtype exhibited a consistent PFS benefit with RIB, except for basal-like.
Note: Reproducció del document publicat a: https://doi.org/10.1200/JCO.20.02977
It is part of: Journal Of Clinical Oncology, 2021, vol. 39, num. 13
URI: https://hdl.handle.net/2445/214816
Related resource: https://doi.org/10.1200/JCO.20.02977
ISSN: 1527-7755
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
A. Prat et al 2021.pdf488.8 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons